looked at common side effects
and provided recommendations
for managing these side effects
May Help Predict
Pediatric PH Morbidity
while useful for adults,
was not intended for use in
children and infants.
VOLT study demonstrated
no new safety issues for
patients taking ambrisentan
in real life situations.
Connect with the
networking, fundraising and
awareness events near you.
PHANews.org, a publication of the Pulmonary Hypertension Association (PHA), is the trusted source of up-to-date news, community events listings and lifesaving information about pulmonary hypertension for patients, families and caregivers, healthcare professionals and supporters.
Washington, D.C. Golden Glove Lightweight Champion Elvis Medrano Faces Biggest Battle with Deadly Lung Disease Diagnosis
Silver Spring, Md. (March 13, 2018) -- In and out of the boxing ring, Washington, D.C., Golden Glove lightweight champion Elvis Medrano is in a daily battle for his
Dear PH Professionals: If you received a copy of PH Clinical Quick Reference Guide, please discard. Page 1 of the guide “Classifying PH,” incorrectly states that an elevated pulmonary artery
Dear PHA Community Member: Every year, spring marks the beginning of the pulmonary hypertension (PH) community’s annual fundraising events to support the Pulmonary Hypertension Association (PHA) and its mission –
PHA support group leader volunteers take on many roles in the pulmonary hypertension (PH) community. Many are living with PH -- others are caregivers or health care professionals --
Tucson, Ariz. (March 5, 2018) - The regulars who get their steps in early at Sabino Canyon National Park have come to know Eric Simmons, at least by face.
Raele Robison was a student in a demanding PhD program when she was diagnosed with scleroderma and pulmonary hypertension. Now armed with answers about what was causing her mysterious symptoms,
Seven new videos — four in English and three in Spanish — are now live on PHA Classroom. We invite you to view these newly-released “Quick Clips” to get
The Patient Advocate Foundation (PAF) has reopened a co-pay assistance fund for qualifying patients with pulmonary hypertension. PAF is accepting applications for new and renewal patients. The maximum award level
Although the past decades of discovery and research have yielded drugs that improve prognosis and quality of life, the long-term survival rates for people living with PAH is still unacceptably
Silver Spring, Md. (February 22, 2018) -- The Pulmonary Hypertension Association (PHA) joins global partners, Feb. 28, Rare Disease Day®, to bring attention to the hopes and needs of
The 6th World Symposium on Pulmonary Hypertension will take place in Nice, France from Feb. 27 to March 1, 2018. This symposium, held every 5 years, is a time
PHA Accreditation Program Assures Access to Specialized Care for Thousands With Often-Misdiagnosed Deadly Lung Disease
Silver Spring, MD (February 15, 2018) – A national accreditation program launched by the Pulmonary Hypertension Association (PHA) assures that more than 12,000 people with a life-threatening lung disease
Seeking Financial Assistance Because of Caring Voice Developments? Previous CVC Clients Should Make That Clear When Contacting Manufacturers.
In January, the Department of Health and Humans Services informed companies that manufacture PH medications that they would be permitted to provide one year of free medication to some individuals
Study looks at a theory that adding immunoadsorption, or the process of filtering out antibodies from the blood, in addition to other PH therapies may help improve outcomes for people
WHO Group 1 PH (PAH, pulmonary arterial hypertension) can appear by itself of be associated with other medical conditions including connective tissue diseases (CTD), such as systemic lupus erythematosus (SLE).
PHA was recently made aware of a national shortage of the diluent used for mixing some PH medications. The shortage is a result of product manufactures who have been affected
Investigator Applications are now being accepted for the Research Room at PHA’s 2018 International PH Conference and Scientific Sessions. The Research Room helps researchers further their studies by providing the
by Phyllis Hanlon, Contributing Writer WHO Group 1 PH (PAH, pulmonary arterial hypertension) is a progressive and chronic disease. There currently is no cure. In PAH, the arteries in
Friday, February 9th, 2018, 3:00 p.m. ET Josanna M. Rodriguez-Lopez, M.D., Massachusetts General Hospital This webinar will focus on WHO Group 4 pulmonary hypertension (PH), chronic thromboembolic pulmonary hypertension
On Monday, January 15, 2018, President Trump signed into law the Recognize, Assist, Include, Support and Engage (RAISE) Family Caregivers Act calling for a national strategy to address the needs of family caregivers. This bipartisan
Thanks to Our Sponsors
Interested in advertising?
PHA offers various advertising and sponsorship opportunities on PHANews.org for companies and non-profit organizations. Please contact Advertisements@PHAssociation.org for more information.